161 related articles for article (PubMed ID: 17487746)
1. Immuno-chemotherapy with a combination of rituximab, methotrexate, pirarubicin and procarbazine for patients with primary CNS lymphoma--a preliminary report.
Yamanaka R; Homma J; Sano M; Tsuchiya N; Yajima N; Shinbo Y; Hasegawa A; Onda K; Tanaka R
Leuk Lymphoma; 2007 May; 48(5):1019-22. PubMed ID: 17487746
[No Abstract] [Full Text] [Related]
2. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
Fritsch K; Kasenda B; Hader C; Nikkhah G; Prinz M; Haug V; Haug S; Ihorst G; Finke J; Illerhaus G
Ann Oncol; 2011 Sep; 22(9):2080-2085. PubMed ID: 21303800
[TBL] [Abstract][Full Text] [Related]
3. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
Shah GD; Yahalom J; Correa DD; Lai RK; Raizer JJ; Schiff D; LaRocca R; Grant B; DeAngelis LM; Abrey LE
J Clin Oncol; 2007 Oct; 25(30):4730-5. PubMed ID: 17947720
[TBL] [Abstract][Full Text] [Related]
4. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome.
Morris PG; Correa DD; Yahalom J; Raizer JJ; Schiff D; Grant B; Grimm S; Lai RK; Reiner AS; Panageas K; Karimi S; Curry R; Shah G; Abrey LE; DeAngelis LM; Omuro A
J Clin Oncol; 2013 Nov; 31(31):3971-9. PubMed ID: 24101038
[TBL] [Abstract][Full Text] [Related]
5. Salvage immuno-chemotherapy with a combination of rituximab, high-dose cytarabine, mitoxantrone and dexamethasone for patients with primary CNS lymphoma: a preliminary study.
Yamanaka R; Homma J; Sano M; Tsuchiya N; Yajima N; Takahashi H; Shinbo Y; Hasegawa A; Saitoh T; Tanaka R
Leuk Lymphoma; 2007 Jul; 48(7):1429-33. PubMed ID: 17613777
[No Abstract] [Full Text] [Related]
6. Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.
Chihara D; Fowler NH; Oki Y; Fanale MA; Fayad LE; Westin JR; Hagemeister FB
Br J Haematol; 2017 Dec; 179(5):851-854. PubMed ID: 27502933
[No Abstract] [Full Text] [Related]
7. Modified ProMACE-MOPP hybrid regimen with moderate-dose methotrexate for patients with primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Takeuchi S; Tamura T; Hondoh H; Takahashi H; Onda K; Takahashi H; Tanaka R
Ann Hematol; 2005 Jul; 84(7):447-55. PubMed ID: 15747120
[TBL] [Abstract][Full Text] [Related]
8. Results of treatment of 112 cases of primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
[TBL] [Abstract][Full Text] [Related]
9. Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy.
Sasaki N; Kobayashi K; Saito K; Shimizu S; Suzuki K; Lee J; Yamagishi Y; Shibahara J; Takayama N; Shiokawa Y; Nagane M
Jpn J Clin Oncol; 2020 Sep; 50(9):999-1008. PubMed ID: 32469065
[TBL] [Abstract][Full Text] [Related]
10. Rituximab, methotrexate, procarbazine, vincristine and intensified cytarabine consolidation for primary central nervous system lymphoma (PCNSL) in the elderly: a LOC network study.
Houillier C; Ghesquières H; Chabrot C; Soussain C; Ahle G; Choquet S; Nicolas-Virelizier E; Bay JO; Vargaftig J; Gaultier C; Touitou V; Martin-Duverneuil N; Cassoux N; Le Garff-Tavernier M; Costopoulos M; Faurie P; Hoang-Xuan K
J Neurooncol; 2017 Jun; 133(2):315-320. PubMed ID: 28432587
[TBL] [Abstract][Full Text] [Related]
11. Salvage therapy and late neurotoxicity in patients with recurrent primary CNS lymphoma treated with a modified ProMACE-MOPP hybrid regimen.
Yamanaka R; Shinbo Y; Sano M; Homma J; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Morii K; Onda K; Tanaka R
Leuk Lymphoma; 2007 Jun; 48(6):1119-26. PubMed ID: 17577775
[TBL] [Abstract][Full Text] [Related]
12. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas.
Wong ET; Tishler R; Barron L; Wu JK
Cancer; 2004 Jul; 101(1):139-45. PubMed ID: 15221999
[TBL] [Abstract][Full Text] [Related]
13. Factors influencing the response to high dose methotrexate-based vincristine and procarbazine combination chemotherapy for primary central nervous system lymphoma.
Sung KH; Lee EH; Kim YZ
J Korean Med Sci; 2011 Apr; 26(4):551-60. PubMed ID: 21468264
[TBL] [Abstract][Full Text] [Related]
14. [Clinical Analysis of Combination Chemotherapy Using High Dose Methotrexate, Rituximab, and Vincristine with or without Procarbazine for Elderly Patients with Diffuse Large B-Cell Lymphoma of the Central Nervous System].
Okamoto S; Tanaka M; Goto T; Nakashima M; Nagura E
Gan To Kagaku Ryoho; 2017 Dec; 44(13):2109-2112. PubMed ID: 29361628
[TBL] [Abstract][Full Text] [Related]
15. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma.
Korfel A; Martus P; Nowrousian MR; Hossfeld DK; Kirchen H; Brücher J; Stelljes M; Birkmann J; Peschel C; Pasold R; Fischer L; Jahnke K; Thiel E;
Br J Haematol; 2005 Jan; 128(2):177-83. PubMed ID: 15638851
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
18. Isolated central nervous system relapse in a patient with diffuse large B cell lymphoma.
Sato K; Uchiyama M
BMJ Case Rep; 2012 Jan; 2012():. PubMed ID: 22665914
[No Abstract] [Full Text] [Related]
19. Methotrexate and temozolomide versus methotrexate, procarbazine, vincristine, and cytarabine for primary CNS lymphoma in an elderly population: an intergroup ANOCEF-GOELAMS randomised phase 2 trial.
Omuro A; Chinot O; Taillandier L; Ghesquieres H; Soussain C; Delwail V; Lamy T; Gressin R; Choquet S; Soubeyran P; Huchet A; Benouaich-Amiel A; Lebouvier-Sadot S; Gyan E; Touitou V; Barrié M; del Rio MS; Gonzalez-Aguilar A; Houillier C; Delgadillo D; Lacomblez L; Tanguy ML; Hoang-Xuan K
Lancet Haematol; 2015 Jun; 2(6):e251-9. PubMed ID: 26688235
[TBL] [Abstract][Full Text] [Related]
20. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system.
Illerhaus G; Müller F; Feuerhake F; Schäfer AO; Ostertag C; Finke J
Haematologica; 2008 Jan; 93(1):147-8. PubMed ID: 18166803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
